Sjögren's disease & overlap diseases
Estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study
Authors' conclusion
In this large French population database study, the low prevalence of pSS confirms that it is an orphan disease.
Study context
- Population
- Patients with SS identified by algorithm in French national healthcare claims, 2011–2018
- Participants
- 23,848 vs 14,809
- Exposure
- Primary Sjögren's syndrome (pSS) vs SS+AID
- pSSn = 23,848
- SS+AIDn = 14,809
- Outcome
- Prevalence, incidence and mortality rates, and annual healthcare costs of pSS and SS+AID
- Follow-up
- 2011–2018
Methodological detailsnational healthcare claims-based, Système National des Données de Santé database
- National healthcare claims-based
- Système National des Données de Santé database
Main finding
As reported in the abstract
Prevalence rate per 100 000, 2011 to 2018
| Group | Value | Females |
|---|---|---|
| pSS | 23-32 per 100000 | 90%-91% |
| SS+AID | 16-20 per 100 000 | 92%-93% |
Value
pSS23-32 per 100000
SS+AID16-20 per 100 000
Females
pSS90%-91%
SS+AID92%-93%
Observational data: associations, not effects.
Further findings
Incidence rate per 100 000 persons, 2012
Incidence rate per 100 000 persons, 2017 (decreased from 2012)
| Outcome | pSS | SS+AID |
|---|---|---|
| Mortality rate per 100 000 persons, 2012 to 2018 (increased) | 0.2-0.8 per 100 000 | 0.1-0.5 per 100 000 |
Mortality rate per 100 000 persons, 2012 to 2018 (increased)
- Mean age of death also increased
Healthcare use and costs · 2011–2018
- Artificial tears and HCQ were the most common drug reimbursements
- Less than half of patients received annual specialist care from a dentist or ophthalmologist
- SS-associated healthcare costs increased from 2011 to 2018 and exceeded the national estimate of expected costs for chronic diseases
Original publication
Estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study. RMD Open. Published 2 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →